NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...

In trading on Friday, shares of Vertex Pharmaceuticals, Inc. (Symbol: VRTX) crossed above their 200 day moving average of $458.68, changing hands as high as $469.00 per share. Vertex ...

Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Vertex Pharmaceuticals, Inc. (Symbol: VRTX), where a total of 13,551 contracts have traded ...

Investors in Vertex Pharmaceuticals, Inc. (Symbol: VRTX) saw new options become available today, for the March 14th expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...

Vertex Pharmaceuticals (VRTX) closed the most recent trading day ... Meanwhile, the Dow gained 0.31%, and the Nasdaq, a tech-heavy index, added 2.03%. Heading into today, shares of the drugmaker ...

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...

Vertex Pharmaceuticals (VRTX) closed at $428 in the latest trading ... Meanwhile, the Dow gained 0.3%, and the Nasdaq, a tech-heavy index, added 1.28%. Shares of the drugmaker have appreciated ...

Vertex Pharmaceuticals (VRTX) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known ...